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Abstract
Aims There are limited data on whether clinical presentation at ﬁrst heart failure (HF) hospitalization predicts recurrent HF
events. We aimed to assess predictors of recurrent HF hospitalizations in mild HF patients with an implantable cardioverter
deﬁbrillator or cardiac resynchronization therapy with deﬁbrillator.
Methods and results Data on HF hospitalizations were prospectively collected for patients enrolled in MADIT-CRT.
Predictors of recurrent HF hospitalization (HF2) after the ﬁrst HF hospitalization were assessed using Cox proportional hazards
regression models including baseline covariates and clinical presentation or management at ﬁrst HF hospitalization. There
were 193 patients with ﬁrst HF hospitalization, and 156 patients with recurrent HF events. Recurrent HF rate after the ﬁrst
HF hospitalization was 43% at 1 year, 52% at 2 years, and 55% at 2.5 years. Clinical signs and symptoms, medical treatment,
or clinical management of HF at ﬁrst HF admission was not predictive for HF2. Baseline covariates predicting recurrent HF
hospitalization included prior HF hospitalization (HR = 1.59, 95% CI: 1.15–2.20, P = 0.005), digitalis therapy (HR = 1.58, 95%
CI: 1.13–2.20, P = 0.008), and left ventricular end-diastolic volume >240 mL (HR = 1.62, 95% CI: 1.17–2.25, P = 0.004).
Conclusions Recurrent HF events are frequent following the ﬁrst HF hospitalization in patients with implanted implantable
cardioverter deﬁbrillator or cardiac resynchronization therapy with deﬁbrillator. Neither clinical presentation nor clinical
management during ﬁrst HF admission was predictive of recurrent HF. Prior HF hospitalization, digitalis therapy, and left
ventricular end-diastolic volume at enrolment predicted recurrent HF hospitalization, and these covariates could be used as
surrogate markers for identifying a high-risk cohort.
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Introduction
Most clinical trials conducted in heart failure (HF) patients uti-
lized the endpoint of time to ﬁrst HF hospitalization. However,
given that HF is generally a chronic condition characterized by
recurrent hospitalizations, it may be more relevant to assess
recurrent HF hospitalization events, and predictors of recur-
rent HF hospitalization events to identify high-risk cohorts.
In MADIT-CRT, it was shown that cardiac resynchronization
therapy with deﬁbrillator (CRT-D) was associated with reduc-
tion in the risk of recurrent HF events.1 Data are however not
available on risk factors for recurrent HF hospitalization in pa-
tients with mild HF and an implantable cardioverter deﬁbrilla-
tor (ICD) or CRT-D. Furthermore, the predictive value of
parameters at the ﬁrst HF admission to predict recurrent HF
hospitalizations is not well understood. Speciﬁcally, it is not
known whether the clinical presentation or clinical manage-
ment during the ﬁrst HF hospitalization is associated with risk
for recurrent HF hospitalization.
Therefore, in this substudy from MADIT-CRT, we aimed to
characterize patients at the time of their ﬁrst HF hospitaliza-
tion and describe predictive factors for recurrent hospital
OR IG INAL RESEARCH ART ICLE
© 2017 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
ESC HEART FAILURE
ESC Heart Failure 2017; 4: 520–526
Published online 17 June 2017 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/ehf2.12157
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium,
provided the original work is properly cited, the use is non-commercial and no modiﬁcations or adaptations are made.
admission for HF using (i) clinical parameters at enrolment in
the study, (ii) clinical presentation of HF at ﬁrst HF hospitali-
zation, and (iii) clinical management of HF during the initial
HF admission.
Methods
Study population
The design, protocol, and results of theMADIT-CRT study have
been published previously.2,3 Brieﬂy, 1820 patients with isch-
aemic cardiomyopathy [New York Heart Association (NYHA)
functional class I or II] or non-ischaemic cardiomyopathy
(NYHA functional class II only), LVEF of less than 30%, and a
QRS duration >130 ms were randomized to receive CRT-D or
ICD therapy in a 3:2 ratio. All eligible patients met the guideline
criteria for ICD.4 Patients were excluded if they had an indica-
tion for CRT, implanted pacemaker; NYHA III/IV class in the
past 90 days; or coronary artery bypass graft surgery, percuta-
neous coronary intervention or myocardial infarction within
the past 90 days. A total of 110 hospital centres from North
America and Europe participated in this international multi-
center trial. The study was in compliance with the Declaration
of Helsinki, and all enrolling sites had the protocol approved
by the local institutional review board. All patients provided
informed consent before enrolment. The present study
sample comprised of 1820 patients enrolled in MADIT-CRT.
Analyses were performed on an intention-to-treat basis.
Data acquisition and follow-up
The MADIT-CRT trial was carried out from 22 December 2004
to September 2010. After the device implantation, patients
had an ambulatory follow-up at 1 month and every 3 months
thereafter until the termination of the trial. The mean
follow-up of enrolled patients was 40 ± 28 months. All
patients had clinical evaluation at each follow-up visit or at
any meaningful clinical event.
Endpoints and deﬁnitions
The primary endpoint of the study was the occurrence of a
recurrent HF admission (HF2) after the ﬁrst post-enrolment
HF admission (HF1).
The diagnosis of an HF admission was made by physicians
aware of the implanted devices and required signs and symp-
toms consistent with congestive HF that were responsive to
intravenous decongestive therapy or an augmented decon-
gestive regimen with oral or parenteral medications during
an in-hospital stay. An independent committee blinded to
assigned treatment arm or other clinical information carried
out adjudication of the HF hospitalization events. Data for
patients who experienced recurrent HF admissions within
2 weeks of an initial HF admission were further reviewed to
distinguish ongoing HF events from new recurrent HF events.
Ongoing HF events were classiﬁed as a hospitalization that
occurred within 2 weeks of a prior HF admission in which
the patient continued to experience HF symptoms at hospital
discharge or after outpatient intravenous diuretic therapy.
New recurrent HF events were deﬁned as events occurring
at any time after a prior HF event in which the patient was
considered to be fully stabilized at hospital discharge or after
outpatient intravenous therapy.
Echocardiography methods
Echocardiography images were captured at baseline and
1 year according to a pre-speciﬁed protocol. Recordings
were analysed ofﬂine at an independent echocardiography
core laboratory in a blinded fashion. Left ventricular (LV)
volumes were measured by Simpson’s disk method in the
apical 4-chamber and 2-chamber views, and LVEF was
calculated according to the established American Society of
Echocardiography protocols.
When analysing echocardiographic response to CRT-D and
risk of recurrent HF events, left ventricular end-diastolic
volume (LVEDV), left ventricular end-systolic volume, and left
atrial volume percent changes at 1 year were assessed.
Reverse remodelling effect was deﬁned as percent reduction
in LVEDV, left ventricular end-systolic volume, and left atrial
volume between enrolment and 1 year echocardiogram
(calculated as the difference between 1 year and baseline
volumes, divided by baseline volume).
Statistical analysis
Continuous variables are expressed as mean ± SD. Categorical
data are summarized as frequencies and percentages. Base-
line clinical characteristics were compared between the
pre-speciﬁed subgroups of patients with or without HF2 after
the ﬁrst HF hospitalization event, using Kruskal–Wallis test for
continuous variables, and chi-squared test or Fisher’s exact
test for dichotomous variables, as appropriate.
Cumulative probability of recurrent HF2 by subgroups was
displayed according to the Kaplan–Meier method, with
comparisons of cumulative event rates by the log-rank test.
Multivariate Cox proportional hazards regression analysis
was used to identify predictors for recurrent HF hospitaliza-
tion events after the ﬁrst HF admission. The Cox model was
adjusted for relevant clinical covariates using best subset
regression modelling. Candidate covariates included baseline
parameters that showed univariate differences among the
subgroups, clinical presentation at ﬁrst HF hospital admission,
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and management during ﬁrst HF admission (mechanical
respirator support and mechanical cardiac support).
Treatment arm (CRT-D vs. ICD) was forced in the models
using intention-to-treatment assignment.
All statistical tests were two sided, and a P-value of <0.05
was considered statistically signiﬁcant. Analyses were
carried out with SAS software (version 9.4, SAS Institute, Cary,
NC, USA).
Results
Of the 1820 patients, 193 patients (10.6 %) had HF1, and 156
patients (8.6 %) presented with HF2. There were 31% of
patients experiencing recurrent admissions within 6 months:
the recurrent HF rate was 43% at 1 year, 52% at 2 years, and
55% at 2.5 years (Figure 1).
Figure 1 Cumulative probability of recurrent heart failure hospitalization
after ﬁrst heart failure admission.
Table 1 Baseline clinical characteristics of patients by the presence of recurrent heart failure hospitalization after the ﬁrst heart failure
admission
Clinical characteristic No recurrent HF (N = 193) Recurrent HF (N = 156) P-value
Baseline demographics
Female (n, %) 41 (21) 30 (19) 0.642
CRT-D (n, %) 95 (49) 75 (48) 0.831
Age at enrolment (years) 67.3 ± 9.9 65.1 ± 11.5 0.062
Ischaemic aetiology (n, %) 132 (68) 95 (61) 0.144
QRS duration (ms) 156.7 ± 19.9 156.6 ± 22.0 0.764
LBBB (n, %) 123 (64) 100 (65) 0.879
RBBB (n, %) 21 (11) 21 (14) 0.448
IVCD (n, %) 48 (25) 34 (22) 0.521
Heart rate (bpm) 67.2 ± 10.7 68.8 ± 11.1 0.123
SBP (mmHg) 121.7 ± 16.5 120.4 ± 17.8 0.412
DBP (mmHg) 71.0 ± 10.0 70.4 ± 11.3 0.356
Creatinine (mg/dL) 1.26 ± 0.36 1.27 ± 0.37 0.748
BNP level (pg/mL) 207.3 ± 255.9 181.8 ± 174.0 0.963
Worst NYHA >2 before enrolment (n, %) 15 (8) 26 (17) 0.010
Medical history
Hospitalization in prior year (n, %) 107 (56) 87 (57) 0.833
Prior HF hospitalization (n, %) 74 (40) 82 (54) 0.008
Prior CABG (n, %) 78 (40) 51 (33) 0.137
Diabetes (n, %) 78 (40) 64 (41) 0.869
Hypertension (n, %) 137 (71) 102 (66) 0.342
Prior MI (n, %) 104 (56) 77 (50) 0.331
Smoking (n, %) 19 (10) 27 (18) 0.041
Past atrial arrhythmias (n, %) 33 (17) 25 (16) 0.805
Past ventricular arrhythmias (n, %) 15 (8) 16 (10) 0.402
Baseline medical therapy
ACE inhibitor or ARB (n, %) 181 (94) 150 (96) 0.319
Beta-blocker therapy (n, %) 177 (92) 142 (91) 0.821
Aldosterone (n, %) 47 (24) 61 (39) 0.003
Digitalis (n, %) 40 (21) 58 (37) <0.001
Diuretic (n, %) 145 (75) 133 (85) 0.019
Baseline echocardiographic parameters
LVEF (%) 28.3 ± 3.7 28.3 ± 3.6 0.478
LVEDV (mL) 246.2 ± 60.2 264.9 ± 71.5 0.010
LVESV (mL) 177.5 ± 50.4 191.3 ± 57.4 0.014
LAV (mL) 97.7 ± 22.6 105.6 ± 25.1 0.002
ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; CABG, coronary artery
bypass graft; CRT-D, cardiac resynchronization therapy with deﬁbrillator; DBP, diastolic blood pressure; HF, heart failure; IVCD, intraven-
tricular conduction delay; LAV, left atrial volume; LBBB, left bundle branch block; LVEDV, left ventricular end-diastolic volume; LVEF, left
ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MI, myocardial infarction; NYHA, New York Heart Association
Class; RBBB, right bundle branch block; SBP, systolic blood pressure.
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Baseline clinical characteristics
Clinical characteristics of patients with one vs. recurrent HF
hospitalizations are listed in Table 1. Patients with HF2 more
often had prior HF hospitalization (P = 0.009) (Figure 2) and
NYHA class III HF in their history greater than II, three or more
months prior to enrolment (P = 0.010) than patients with no
recurrent HF hospitalization. However, patients with or with-
out recurrent HF hospitalization had similar aetiology of HF
(ischaemic vs. non-ischaemic), baseline electrocardiogram
morphology (left bundle branch block vs. non-left bundle
branch block), gender, or age at enrolment. Importantly,
assigned treatment of CRT-D vs. ICD (intention-to-treat) was
not different in patients with HF1 or HF2.
A greater proportion of patients with recurrent HF hospi-
talization were prescribed diuretics (P = 0.019), aldosterone
antagonists (P = 0.003), and digitalis (P < 0.001). There were
no signiﬁcant differences in beta-blocker or angiotensin
converting enzyme inhibitor/angiotensin receptor blocker us-
age between the groups, and both medication classes were
prescribed in over 90% in the total cohort.
While left ventricular ejection fraction (LVEF) was similar in
the two groups, patients with recurrent HF had signiﬁcantly
increased left ventricular end-diastolic, end-systolic, and left
atrial volumes at baseline (P < 0.05 for all) (Figure 3 and
Table 1).
Cardiac resynchronization therapy with
deﬁbrillator-induced cardiac reverse remodelling
and recurrent HF hospitalization
Although there were no differences in CRT-D vs. ICD treatment
between the subgroups, we found a positive relationship be-
tween echocardiographic reverse remodelling to CRT-D at
1 year and recurrent HF hospitalizations. Namely, patients
with recurrent HF hospitalizations showed signiﬁcantly less
improvement in LVEF, and reduction in left ventricular end-
diastolic, end-systolic volumes, and left atrial volumes, than
patients with recurrent HF events (P < 0.05 for all) (Table 2).
Baseline clinical parameters predicting recurrent
HF hospitalization
Multivariate analysis demonstrated that patients with HF
hospitalization prior to enrolment had 1.59-fold greater
risk of recurrent HF hospitalization (P = 0.005). Patients with
a LVEDV >240 mL at baseline had a 1.62-fold greater risk
for recurrent HF hospitalization (P = 0.004) (Table 3). Adding
medical therapy to the model yielded similar results, and
only baseline digitalis improved the predictive accuracy
(Table S1).
Clinical presentation, medical therapy, and
mechanical support at ﬁrst HF admission and
recurrent HF hospitalization
Clinical symptoms at ﬁrst HF admission, orthopnea, or parox-
ysmal nocturnal dyspnoea were not associated with an
increased risk for recurrent HF admission. Weight before or
Figure 2 Cumulative probability of recurrent heart failure hospitalization
after ﬁrst heart failure admission by prior heart failure hospitalization
before enrolment.
Figure 3 Cumulative probability of recurrent heart failure hospitalization
after ﬁrst heart failure admission by left ventricular end-diastolic volume
greater than 240 mL at baseline.
Table 2 Echocardiographic changes at 12 months after device
implantation in the CRT-D arm (efﬁcacy analysis) by the presence
of subsequent HF hospitalization after the ﬁrst HF admission
Echocardiographic
change N
No recurrent
HF
Recurrent
HF P-value
LVEF change 94 9.5 ± 4.7 6.7 ± 5.1 0.008
LVEDV percent change 94 16.8 ± 9.0 12.6 ± 10.0 0.025
LVESV percent change 94 27.4 ± 13.2 20.1 ± 15.1 0.015
LAV percent change 94 24.4 ± 13.6 20.3 ± 11.5 0.143
HF, heart failure; LAV, left atrial volume; LVEDV, left ventricular
end-diastolic volume; LVEF, left ventricular ejection fraction;
LVESV, left ventricular end-systolic volume.
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after the admission was not predictive of recurrent HF
events. Similarly, ﬁndings at hospital admission, including
oedema, pulmonary congestion, or rales, were not associated
with an increased risk of HF readmission in univariate analy-
ses (Table 4).
Furthermore, there was no association between inpatient
management during HF1, including the use of intravenous di-
uretics, need for mechanical cardiac or respiratory support,
and the risk for recurrent HF admission (Table 5).
Discussion
In this MADIT-CRT sub-study, we have identiﬁed important
baseline clinical factors, predicting recurrent HF hospitaliza-
tion. Risk factors at study enrolment included previous HF
admission, increased LVEDV index, and digitalis therapy.
Interestingly, signs or symptoms at the time of initial HF
admission, or medical management during ﬁrst HF hospitali-
zation, were not predictive for recurrent HF admission.
Despite novel HF therapies, hospital readmission rates
remain high5 and are associated with signiﬁcant increase in
the risk of all-cause mortality. Therefore, it is essential to
identify patients with a high risk for recurrent HF admissions
and intensify their follow-up and treatment.
Previous studies have shown baseline patient characteris-
tics to be associated with signiﬁcant risk of HF readmission,
although there is a relative lack of consensus between stud-
ies.6–8 Furthermore, data are scarce on predictors of recur-
rent HF hospitalization, especially in patients with mild HF
and an implanted ICD or CRT-D. The present study therefore
provides relevant information for the clinician with important
clinical implications.
First, we found that prior HF hospitalization is a strong
predictor for recurrent HF hospitalizations. This is consistent
with prior studies showing history of a prior HF hospitaliza-
tion is perhaps the strongest, most consistent risk factor for
HF rehospitalization.9
Our study also found LVEDV to be a signiﬁcant predictor of
recurrent HF hospitalization. This is in agreement with prior
studies showing a higher LVEDV to be associated with worse
outcomes in HF patients, including death and HF hospi-
talization.10,11 It is likely that increased dilation of the left
ventricle correlates with more advanced stages of myocardial
Table 3 Predictors for recurrent heart failure hospitalization considering baseline parameters, and clinical presentation and management
of patients at ﬁrst heart failure hospitalization
Patients/events: 337/152 Hazard ratio 95% conﬁdence interval P-value
LVEDV index greater than 240 mL at baseline 1.62 1.17–2.25 0.004
Prior CHF hospitalization before enrolment 1.59 1.15–2.20 0.005
LVEDV, left ventricular end-diastolic volume.
The model was further adjusted for cardiac resynchronization therapy with deﬁbrillator vs. implantable cardioverter deﬁbrillator assigned
treatment.
Table 4 Symptoms and clinical presentation at the time of ﬁrst heart failure hospitalization by the presence of recurrent heart failure hos-
pitalization after the ﬁrst heart failure admission
Clinical presentation No recurrent HF Recurrent HF P-value
Paroxysmal nocturnal dyspnoea (n, %) 59 (44) 47 (41) 0.541
Orthopnea (n, %) 67 (46) 71 (55) 0.130
Presence of rales at admission (n, %) 0.8 ± 0.7 0.8 ± 0.7 0.276
Pulmonary congestion (n, %) 1.0 ± 0.9 1.2 ± 0.9 0.190
Oedema (n, %) 1.0 ± 1.0 0.9 ± 1.0 0.468
Weight before admission (kg) 87.2 ± 18.1 88.3 ± 19.2 0.876
Weight after admission (kg) 84.0 ± 17.6 82.6 ± 17.4 0.781
HF, heart failure.
Table 5 Medical and mechanical therapy during the ﬁrst heart failure hospitalization by the presence of recurrent heart failure hospital-
ization after the ﬁrst heart failure admission
Medical therapy No recurrent HF Recurrent HF P-value
Oral diuretics (n, %) 104 (56) 88 (58) 0.757
Iv. diuretics (n, %) 171 (92) 142 (92) 0.914
Oral beta-blocker (n, %) 40 (22) 30 (20) 0.702
Oral ACE inhibitor (n, %) 23 (13) 25 (17) 0.282
Oral ARB (n, %) 7 (4) 7 (5) 0.688
Oral aldosterone antagonist (n, %) 9 (5) 11 (7) 0.358
Iv. inotrope therapy (n, %) 18 (10) 22 (15) 0.199
Mechanical respirator support (n, %) 21 (11) 15 (10) 0.699
ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; Iv., intravenous therapy.
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remodelling, and thus with a more tenuous haemodynamic
state at baseline and a consequently increased predisposition
to recurrent decompensation. Conversely, our study did not
show LVEF to be a signiﬁcant predictor of recurrent HF admis-
sion. Indeed, LVEF has only inconsistently been associated
with HF outcomes, with only a few studies to our knowledge
demonstrating a signiﬁcant association between lower LVEF
and HF re-admission.11,12
We also revealed a signiﬁcant association between base-
line digitalis therapy and risk of HF re-admission. Although
prior data have shown that digoxin therapy is associated with
a decreased risk of HF re-admission in patients in sinus
rhythm,13 it is plausible that in our population of mildly symp-
tomatic HF patients, digitalis treatment serves as a surrogate
marker for sicker patients.
Furthermore, we investigated left ventricular reverse
remodelling in patients with or without recurrent HF hospi-
talization. We found that patients implanted with CRT-D pre-
senting with no recurrent HF hospitalization had better
echocardiographic reverse remodelling as compared with pa-
tients with recurrent HF events. This ﬁnding further empha-
sizes the role of post CRT-D implantation echocardiography
in the clinical management of such patients.
Interestingly, in our study, there was no association be-
tween presenting signs or symptoms at ﬁrst HF admission
and risk of recurrent re-admission. To our knowledge, there
has only been sparse evidence linking such presenting factors
to risk of recurrent HF re-admission.8 One potential explana-
tion for this ﬁnding is that the signs and symptoms of a HF
exacerbation at the time of hospital presentation, such as
dyspnoea, peripheral oedema, and pulmonary rales, tend to
be relatively ubiquitous.
While we have previously investigated the role of CRT in
ﬁrst and recurrent HF events in patients enrolled in MADIT-
CRT,1 we did not speciﬁcally assess predictors for recurrent
HF events. The current study further extends our prior ﬁnd-
ings and may help guiding the clinician to identify patients
at particularly high risk for recurrent HF hospitalization.
Our study was limited primarily by the fact that our popu-
lation was a composite of patients with two different device
therapies, CRT-D and ICD. Thus, the identiﬁed risk factors
for the population as a whole may not necessarily apply to
both treatment arms. Additionally, the relatively small num-
ber of patients with a recurrent HF event during the study
follow-up period may have resulted in limited statistical
power to detect further differences.
Limitations
Our sub-study has some certain limitations: ﬁrst, as we were
focusing on CRT-D induced reverse remodelling and its rela-
tion with recurrent HF admissions, patients on ICD arm were
excluded from the current analysis. Second, there was brain
natriuretic peptide measurement only at index hospitalization
at baseline, no cardiac troponin or brain natriuretic peptide
levels were detected during the rehospitalization events,
which could provide more information about the severity of
the event. Third, the concomitant medications were shown
only during the ﬁrst HF events, while changes in medical treat-
ment between the ﬁrst and second HF events were not specif-
ically analysed in this study because of lack of detailed data.
Conclusions
Clinical presentation at initial HF hospitalization does not
predict risk for recurrent HF admission in patients with mild
systolic HF and an implanted ICD or CRT-D. Prior HF hospital-
ization, larger LV volumes, and digitalis therapy at baseline
were associated with an increased risk for recurrent HF
admissions. Patients implanted with CRT-D presenting with
recurrent HF events had less favourable echocardiographic
reverse remodelling.
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